Literature DB >> 18496664

[Elective organ-sparing surgery for renal tumors in patients with a normal contralateral kidney: long-term results].

F C Roos1, S Pahernik, W Brenner, J W Thüroff.   

Abstract

Continuous improvements in radiological imaging techniques have enabled an earlier diagnosis of incidental renal tumors. The share of small renal tumors (<or=4 cm, T1a) amongst the incidentally detected renal masses is reported to be as high as 60%. Fortunately, the classic clinical triad of pain, hematuria, and a palpable flank mass is nowadays the exception of clinical presentation. Concerns regarding development of chronic renal failure after radical nephrectomy have resulted in an increasing use and steady improvement of organ-sparing surgical techniques for patients with small unilateral renal tumors in the presence of a normal contralateral kidney (elective indication). Nephron-sparing surgery has become the gold standard for treating these small tumors. Newer long-term oncological results have demonstrated that carefully selected patients with unilateral renal tumors >4 cm can also be treated with nephron-sparing surgery. We report in this article our long-term oncological results of nephron-sparing surgery in patients with an elective indication.

Entities:  

Mesh:

Year:  2008        PMID: 18496664     DOI: 10.1007/s00120-008-1713-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm.

Authors:  Frank Becker; Stefan Siemer; Markus Hack; Ulrich Humke; Manfred Ziegler; Michael Stöckle
Journal:  Eur Urol       Date:  2006-03-23       Impact factor: 20.096

2.  Nephron-sparing surgery compared with radical nephrectomy for renal tumors: current indications and results.

Authors:  R Indudhara; A J Bueschen; D A Urban; J R Burns; L K Lloyd
Journal:  South Med J       Date:  1997-10       Impact factor: 0.954

3.  Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the cell carcinoma.

Authors:  V VERMOOTEN
Journal:  J Urol       Date:  1950-08       Impact factor: 7.450

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

5.  Conservative surgery of renal cell tumors in 140 patients: 21 years of experience.

Authors:  F Steinbach; M Stöckle; S C Müller; J W Thüroff; S W Melchior; R Stein; R Hohenfellner
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

6.  Elective nephron sparing surgery for renal cell carcinoma larger than 4 cm.

Authors:  Sascha Pahernik; Frederik Roos; Bernd Röhrig; Christoph Wiesner; Joachim W Thüroff
Journal:  J Urol       Date:  2007-11-12       Impact factor: 7.450

7.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

8.  Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability?

Authors:  Vincenzo Ficarra; Giacomo Novara; Antonio Galfano; Giovanni Novella; Dionisio Schiavone; Walter Artibani
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

Review 9.  Clinical experience with nephron-sparing surgery in the presence of a normal contralateral kidney.

Authors:  F Steinbach; M Stöckle; R Hohenfellner
Journal:  Semin Urol Oncol       Date:  1995-11

10.  Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.

Authors:  S E Lerner; C A Hawkins; M L Blute; A Grabner; P C Wollan; J T Eickholt; H Zincke
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.